Background Expression of P2X 7 , an ATP-gated calcium channel, increases cancer cell proliferation and invasiveness. A variant of P2X 7 (termed nfP2X 7 ), in which a normally hidden epitope (E200) is exposed for antibody binding, is observed in a variety of different cancers. Objectives To investigate the safety, tolerability and pharmacokinetics and assess indicative efficacy of a novel antibody ointment as a therapeutic for basal cell carcinoma (BCC). Methods An open-label, phase I clinical trial was undertaken at three dermatology clinics to evaluate the safety and tolerability of topical administration of an ointment containing 10% sheep polyclonal anti-nfP2X 7 antibodies (BIL010t) to primary BCC lesions twice daily for 28 days. Twenty-one patients with primary BCC lesions at least 0Á5 cm 2 in area and less than 2Á0 cm in diameter were
Summary
Background Expression of P2X 7 , an ATP-gated calcium channel, increases cancer cell proliferation and invasiveness. A variant of P2X 7 (termed nfP2X 7 ) , in which a normally hidden epitope (E200) is exposed for antibody binding, is observed in a variety of different cancers. Objectives To investigate the safety, tolerability and pharmacokinetics and assess indicative efficacy of a novel antibody ointment as a therapeutic for basal cell carcinoma (BCC) . Methods An open-label, phase I clinical trial was undertaken at three dermatology clinics to evaluate the safety and tolerability of topical administration of an ointment containing 10% sheep polyclonal anti-nfP2X 7 antibodies (BIL010t) to primary BCC lesions twice daily for 28 days. Twenty-one patients with primary BCC lesions at least 0Á5 cm 2 in area and less than 2Á0 cm in diameter were enrolled. The primary end points were safety, tolerability and pharmacokinetics. Change in lesion size after treatment was determined and histology was performed on pretreatment and end-of-treatment (EOT) biopsies.
Results Compliance was very high, with treatment being well tolerated. The most common adverse events were treatment site erythema, pruritus, dryness and pain. There was no evidence of systemic penetration of the sheep antibody. Lesions were measured prior to and after 28 days of treatment, with 65% of patients showing a reduction in lesion area, 20% showing no change and 15% showing an increase. Histopathology of post-treatment excision of lesion sites showed eight patients with stable disease, nine with partial response and three with complete response. Conclusions Antibodies against nfP2X 7 (BIL010t) provide a novel, safe and welltolerated treatment for BCC.
What's already known about this topic?
• nfP2X 7 is a form of the ATP-gated P2X 7 receptor in which the E200 epitope is exposed for antibody binding.
• nfP2X 7 is highly expressed in several cancers, including melanoma.
What does this study add?
• A mouse model of melanoma is used to demonstrate that topical application of anti-nfP2X 7 antibodies is effective in reducing lesion size.
• Expression of nfP2X 7 in basal cell carcinoma is demonstrated by immunohistochemistry.
• A phase I clinical trial demonstrates that topical application of an ointment containing anti-nfP2X 7 antibodies to basal cell carcinomas is well tolerated and provides early indications of efficacy.
Nonmelanoma skin cancer (NMSC) is extremely common. The lifetime risk of developing NMSC is estimated to be one in five, with the majority of cases being basal cell carcinoma (BCC). [17] [18] [19] or by binding of proteins associated with the P2X 7 signalling complex. 20 An epitope termed E200 that is associated with nonfunctional forms of the P2X 7 receptors has been identified. [21] [22] [23] The E200 epitope is exposed on P2X 7 on the surface of cancer cells but not on normal, noncancerous cells. This form of the receptor, termed nfP2X 7 , can be specifically targeted with antibodies raised against the exposed E200 sequence. The nfP2X 7 receptor has been shown to be upregulated in multiple cancers including breast, prostate and melanoma. [24] [25] [26] [27] Here, sheep polyclonal antibodies raised against the E200 epitope of nfP2X 7 have been investigated as a topical treatment for skin cancers with a focus on BCC.
Materials and methods
Preclinical mouse model 
Production of sheep polyclonal anti-E200 antibody and BIL010t
Anti-nfP2X 7 antibody was manufactured by repeatedly immunizing sheep with the P2X 7 E200 sequence (GHNYTTR-NILPGLNITC) 21, 22 conjugated to keyhole limpet haemocyanin followed by the collection of sera and purification of IgG as the API. The API used in this clinical trial was purified from sera using the mercaptoethylpyridine HyperCel hydrophobic charge induction chromatography fractionation process with acid elution, followed by diafiltration. Virus inactivation was achieved through two orthogonal approaches, a low-pH hold and ultrafiltration. The API was lyophilized, and the freeze-dried powder was formulated into an ointment, BIL010t, containing 59Á4% PEG 400, 29Á7% PEG 3350 and 0Á9% phenoxyethanol. BIL010t drug product contained 100 mg API per gram of ointment (10%).
Immunohistochemistry
Five-micrometre-thick sections were cut from formalin-fixed paraffin-embedded tissue from BCC lesions and mounted on glass slides. Heat-induced epitope retrieval was carried out by incubation in Biocare Universal Decloaker (Biocare, Pacheco, CA, U.S.A.) solution for 50 min at 98°C. Sections were stained with mouse monoclonal anti-E200 antibody (BPM09) primary for 60 min followed by Mach 4 mouse probe (Biocare) for 15 min and Mach 4 universal polymer horseradish peroxidase for 25 min. Each step was separated by tissue rinsing for 5 min in Tris-buffered saline. Dako liquid diaminobenzidine (DAB; Dako, Carpinteria, CA, U.S.A.) was used as chromagen (5 min) and haematoxylin (5 s) was used as the counterstain. Slides were examined on an Olympus BX41 microscope with 209 objective.
Haematoxylin and eosin staining
Shave biopsies from screening and lesions excised at end of treatment (EOT) were excised for histological examination.
Five-micrometre-thick sections were cut from formalin-fixed paraffin-embedded tissue and mounted on glass slides. Each of the tissue sample sections was stained on a Leica XL autostainer by dewaxing in xylene, hydrating through a series of graded alcohols and rinsed in tap water. Tissue sections were then stained with Mayer's haematoxylin and aqueous eosin and rinsed in tap water. The tissue sections were then dehydrated through a series of graded alcohols, cleared in xylene and mounted with Pertex â (Histolab, Askim, Sweden). Three or four sections from each pretreatment shave biopsy and five or six sections from each excision biopsy were examined by a pathologist.
Clinical trial

Study design
The study design was an open-label, multicentre phase I clinical trial to evaluate the safety and tolerability of topical administration of BIL010t to primary BCC lesions. The primary objectives were to evaluate the safety and tolerability of topical administration of BIL010t, to determine the steady-state pharmacokinetics of the API and to determine levels of human antidrug antibody (ADA) in serum. The study was designed by the Clinical Research Organisation, Biosceptre's clinical consultant, the clinical investigators and Biosceptre. All patients were at least 18 years of age and had one primary, histologically confirmed BCC that was suitable for surgical excision (and not indicated for Mohs surgery). Maximum lesion diameter was 2 cm with a minimum area of 0Á5 cm 2 .
Histological diagnosis was made no more than 4 weeks prior to the screening visit, and the shave biopsy removed no more than 25% of the lesion (histological subtypes are listed in Table 1 ). Lesions on the hands and feet were excluded. The study protocol was approved by Quorum Review Independent Review Board, Seattle, and all patients provided written informed consent prior to commencement of the study.
Study protocol
Twenty-one patients met the study entry criteria and all received treatment with the investigational product (IP) (BIL010t). Patients applied approximately 50-100 mg of BIL010t to an area of approximately 25 cm 2 containing a single BCC lesion twice daily for 28 days. A large treatment area was utilized to examine the safety characteristics of the treatment on both the lesion and the surrounding normal skin. Prior to the morning dose each day, patients desquamated the entire 25-cm 2 treatment area using a 3M Buf-Puf Blood sampling for pharmacokinetic studies was carried out predose at baseline (day 1) and at day 15. At the EOT visit, blood was drawn predose before the final application of IP and postdose at 1 h, 2 h and 4 h. API concentration in blood samples was measured using an anti-sheep IgG enzyme-linked immunosorbent assay. To determine API immunogenicity, blood samples from screening, baseline, day 29 and day 57 were analysed in a bridging format electrochemilluminescence assay for human antisheep IgG antibody. 28 
Results
Preclinical data
Polyclonal antibodies purified from sheep immunized with the E200 peptide were shown to bind specifically to nfP2X 7 expressed on cancer cell lines, but not to functional P2X 7 ( Fig. S1 ; see Supporting Information). These antibodies were formulated into a PEG-based topical ointment.
This was first tested as a topical treatment in an orthotopic mouse model of melanoma. Treatment with ointment containing E200 targeted sheep IgG caused a significant reduction in B16F10 tumour growth compared with all control groups (Fig. 1) [two-way ANOVA with Tukey's multiple comparison test (day 17, P = 0Á02; day 19, P < 0Á01)].
As P2X 7 has been shown to be expressed in NMSCs, including BCC, 29 this was investigated as an indication for treatment with BIL010t. Shave biopsies from BCCs tested for the presence of nfP2X 7 with an E200-targeted monoclonal antibody showed extensive staining for nfP2X 7 by immunohistochemistry (Fig. 2) .
To investigate the possibility that targeting nfP2X 7 may provide a therapeutic option for BCC, the nfP2X 7 -targeted sheep polyclonal ointment was developed as a treatment for BCC. 
Yes
The severity of each treatment site adverse event is listed together with day of onset and day at which event was resolved (day 1 is start of treatment). F, female; M, male.
Extensive independent preclinical toxicology studies were performed. These included immunohistochemistry tissue crossreactivity studies using the API on a full panel of normal human tissues. Binding to the membranes of cells in normal tissues was not seen, but binding to the membrane of control frozen tissue sections from cancer cell lines was observed (data not shown). Independent preclinical toxicology studies were performed in minipigs. These studies, conducted for 28-day (32 minipigs) and 90-day (40 minipigs) periods, demonstrated that the ointment was well tolerated (data not shown).
Phase I clinical trial
The 10% topical ointment (BIL010t) was then used in an open-label phase I clinical trial (clinicaltrials.gov NCT02587819). Participant flow through the trial is shown in Figure 3 . Twenty-six patients with skin lesions initially diagnosed as BCC were assessed for study eligibility. The screening process for each subject included a shave biopsy to confirm the diagnosis of BCC, followed by 25-31 days to enable the site of the shave biopsy to heal. The baseline visit was conducted after the screening period and was designated as 'day 1'. Four patients were excluded as histopathology indicated that their lesion was not a BCC and another patient was excluded based on electrocardiogram results.
Safety and tolerability
The baseline characteristics of the remaining study population of 21 patients are outlined in Table 1 . There was a high level of compliance with the treatment regimen. Twenty of 21 patients completed dosing with one patient lost to follow-up prior to the EOT visit. Eleven patients reported treatment site adverse events (AEs) (recorded in Table 1 ). These included erythema reported in 10 patients, dryness (seven patients), exfoliation and pruritus (both reported in five patients) and application site pain (three patients). Treatment site AEs were Immunohistochemistry (IHC) staining of shave biopsies demonstrates that basal cell carcinomas (BCCs) express nfP2X 7 . Shave biopsies were taken from BCC lesions before treatment and IHC staining, using an nfP2X 7 -targeted monoclonal antibody, showed the nfP2X 7 target to be present. mild to moderate, except for severe erythema, which was reported in three patients.
In addition to treatment site AEs listed in Table 1 , there were three other AEs that were not considered to be related to treatment. Patient 01-006 experienced a serious AE (a cardiac arrest) at day 49 during follow-up. Patient 03-003 experienced mild diarrhoea from day 20 to 24 of treatment and moderate sinusitis from day 41 to 56 of follow-up.
Pharmacokinetics and immunogenicity
Immunogenicity and pharmacokinetics were also examined during the study. Antisheep IgG antibody levels were measured in blood samples taken from patients at screening, baseline, EOT and follow-up on day 57. Results are shown in Figure S2 (see Supporting Information). Eight patients had detectable titres at screening and baseline (prior to first dose) visits, demonstrating that antisheep IgG antibodies exist in the untreated population. Of these eight patients, three showed a twofold increase in titres and one showed a fourfold increase in titres after treatment. Twelve patients were negative at baseline and of these, three patients developed titres (two patients at EOT and one further patient at follow-up). Overall, treatment with BIL010t was not immunogenic in most patients, and in patients who developed ADAs, these were at low titres and did not correlate with AEs.
Pharmacokinetics were examined at the EOT visit. Patients had blood drawn predose and at 1 h, 2 h and 4 h after application of BIL010t. At all time points, the serum concentration of sheep IgG was too low to be quantified in most patients (data not shown). One patient had measurable sheep IgG at 1 h postdose at visit 6 (EOT) and three other patients had measurable sheep IgG at predose time points. These data suggest that there is minimal systemic penetration of BIL010t.
Efficacy
Lesion size in each patient was measured at baseline (day 1) prior to the start of treatment and at day 29 (EOT). A waterfall plot of percentage change in lesion area is shown in Figure 4(a) . Overall, 65% of patients showed a reduction in lesion area after 28 days, 20% showed no change and 15% showed increased lesion size. This outcome provides an initial indication of efficacy that will be investigated further in a subsequent clinical trial.
Haematoxylin and eosin-stained sections from shave biopsies obtained at the screening visit and tumour tissue excised at the EOT visit were examined by an independent pathologist. There were extensive BCC tumour cells present in all screening-visit shave biopsies. Mild inflammation was seen in five of 20 patients. The regression of BCC results in accumulation of fibrous stroma around the tumour. 30, 31 Therefore, the ratio of fibrous stromal reaction to remaining tumour in EOT sections was used to approximate tumour regression (Fig. 4b,  Fig. S3 ; see Supporting Information). In EOT sections from three patients (01-006, 03-002, 03-005) there was no evidence of tumour, suggesting that histological clearance had occurred. In a further nine patients there was evidence of increased fibrous stromal reaction within the tumour margins suggesting partial tumour regression. EOT sections from all patients showed inflammatory reaction with accumulation of lymphocytes around the tumour.
Discussion
This clinical trial is the first to assess safety for an antibodybased treatment of BCC and the first to assess antibodies targeting nfP2X 7 in humans. Preclinical data demonstrate that BIL010t binds specifically to nfP2X 7 , a form of P2X 7 with attenuated pore functionality, and does not bind to fully functional P2X 7 . Formal preclinical studies confirmed that the API of BIL010t does not bind to cell membranes of normal tissue (data not shown). Furthermore, formal toxicology studies, undertaken in minipigs, confirmed the necessary safety to support a phase I clinical trial. Together, these observations demonstrated that BIL010t is highly likely to be safe when used as a topical therapeutic owing to its target specificity and minimal potential for off-target effects. Preclinical studies showed that BIL010t was efficacious in an orthotopic mouse melanoma model, where sheep polyclonal antibodies raised against E200 were able to inhibit the growth of B16F10 cell-line-derived tumours significantly. P2X 7 expression has been previously described in BCC, 29 and immunohistochemistry confirmed the presence of nfP2X 7 in BCC lesions. Therefore, BIL010t was examined as a topical treatment for BCC in a phase I clinical trial in which patients demonstrated a high level of compliance with the treatment regimen, with mainly localized treatment site AEs reported, and no patients discontinuing treatment prematurely as a result of AEs. This demonstrates that BIL010t is both safe and well tolerated in patients with BCC and therefore could be used in a phase II study to establish efficacy. The surface lesion size was measured at baseline and after 28 days of treatment to give an indication of efficacy for BIL010t. Lesion depth was not measured and, therefore, results may not reflect the full extent of efficacy. However, 65% of patients showed a reduction in lesion surface area. In addition, haematoxylin and eosin-stained EOT sections were analysed for signs of regression. Three patients showed no evidence of tumour in EOT sections and a further nine patients showed evidence of partial regression. These data are supportive of the efficacy of BIL010t as a treatment for BCC. However, as the trial was carried out over a short 28-day time frame with limited efficacy measures, these results are not conclusive. Efficacy will be thoroughly evaluated in a carefully designed phase II trial over a longer treatment period. A shave biopsy was taken from all lesions prior to treatment and it is unclear whether this may have affected the penetration of BIL010t into lesions. This will be addressed in further efficacy trials.
There is no apparent correlation between measured lesion size and histological assessment of tumour regression. For example, three patients presenting with increased lesion size all showed evidence of histological regression, including complete histological clearance in patient 03-005. This illustrates the challenges in assessing efficacy using traditional RECIST (Response Evaluation Criteria In Solid Tumours) measurements when macroscopic observations are utilized.
In conclusion, it has been demonstrated that BIL010t, a first-in-class topical antibody therapy targeting nfP2X 7 , is safe for treating BCC. In addition, BIL010t has shown an initial indication of efficacy based on reduced lesion size and histological evidence of regression. These positive outcomes justify additional clinical trials to assess the potential for BIL010t to treat skin cancer. Because of the widespread expression of nfP2X 7 on a broad variety of cancers and the intrinsic safety of the target, [24] [25] [26] [27] additional therapeutic studies targeting nfP2X 7 on multiple solid-tumour types are being considered.
